205 related articles for article (PubMed ID: 20532182)
1. Structural and dynamical effects induced by the anticancer drug topotecan on the human topoisomerase I - DNA complex.
Mancini G; D'Annessa I; Coletta A; Sanna N; Chillemi G; Desideri A
PLoS One; 2010 Jun; 5(6):e10934. PubMed ID: 20532182
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanism of the camptothecin resistance of Glu710Gly topoisomerase IB mutant analyzed in vitro and in silico.
Tesauro C; Morozzo della Rocca B; Ottaviani A; Coletta A; Zuccaro L; Arnò B; D'Annessa I; Fiorani P; Desideri A
Mol Cancer; 2013 Sep; 12(1):100. PubMed ID: 24004603
[TBL] [Abstract][Full Text] [Related]
3. Binding of an Indenoisoquinoline to the topoisomerase-DNA complex induces reduction of linker mobility and strengthening of protein-DNA interaction.
Mancini G; D'Annessa I; Coletta A; Chillemi G; Pommier Y; Cushman M; Desideri A
PLoS One; 2012; 7(12):e51354. PubMed ID: 23236483
[TBL] [Abstract][Full Text] [Related]
4. Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.
van Waardenburg RC; de Jong LA; van Eijndhoven MA; Verseyden C; Pluim D; Jansen LE; Bjornsti MA; Schellens JH
J Biol Chem; 2004 Dec; 279(52):54502-9. PubMed ID: 15471886
[TBL] [Abstract][Full Text] [Related]
5. Molecular principle of topotecan resistance by topoisomerase I mutations through molecular modeling approaches.
Pan P; Li Y; Yu H; Sun H; Hou T
J Chem Inf Model; 2013 Apr; 53(4):997-1006. PubMed ID: 23521602
[TBL] [Abstract][Full Text] [Related]
6. Antitumour drugs impede DNA uncoiling by topoisomerase I.
Koster DA; Palle K; Bot ES; Bjornsti MA; Dekker NH
Nature; 2007 Jul; 448(7150):213-7. PubMed ID: 17589503
[TBL] [Abstract][Full Text] [Related]
7. The mechanism of topoisomerase I poisoning by a camptothecin analog.
Staker BL; Hjerrild K; Feese MD; Behnke CA; Burgin AB; Stewart L
Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15387-92. PubMed ID: 12426403
[TBL] [Abstract][Full Text] [Related]
8. The human topoisomerase 1B Arg634Ala mutation results in camptothecin resistance and loss of inter-domain motion correlation.
D'Annessa I; Tesauro C; Wang Z; Arnò B; Zuccaro L; Fiorani P; Desideri A
Biochim Biophys Acta; 2013 Dec; 1834(12):2712-21. PubMed ID: 24096022
[TBL] [Abstract][Full Text] [Related]
9. Mutation of Gly717Phe in human topoisomerase 1B has an effect on enzymatic function, reactivity to the camptothecin anticancer drug and on the linker domain orientation.
Wang Z; D'Annessa I; Tesauro C; Croce S; Ottaviani A; Fiorani P; Desideri A
Biochim Biophys Acta; 2015 Aug; 1854(8):860-8. PubMed ID: 25910424
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of camptothecin resistance by human topoisomerase I mutations.
Chrencik JE; Staker BL; Burgin AB; Pourquier P; Pommier Y; Stewart L; Redinbo MR
J Mol Biol; 2004 Jun; 339(4):773-84. PubMed ID: 15165849
[TBL] [Abstract][Full Text] [Related]
11. A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.
Marchand C; Antony S; Kohn KW; Cushman M; Ioanoviciu A; Staker BL; Burgin AB; Stewart L; Pommier Y
Mol Cancer Ther; 2006 Feb; 5(2):287-95. PubMed ID: 16505102
[TBL] [Abstract][Full Text] [Related]
12. Immunodetection of human topoisomerase I-DNA covalent complexes.
Patel AG; Flatten KS; Peterson KL; Beito TG; Schneider PA; Perkins AL; Harki DA; Kaufmann SH
Nucleic Acids Res; 2016 Apr; 44(6):2816-26. PubMed ID: 26917015
[TBL] [Abstract][Full Text] [Related]
13. Activity of Topotecan toward the DNA/Topoisomerase I Complex: A Theoretical Rationalization.
Bali SK; Marion A; Ugur I; Dikmenli AK; Catak S; Aviyente V
Biochemistry; 2018 Mar; 57(9):1542-1551. PubMed ID: 29412654
[TBL] [Abstract][Full Text] [Related]
14. Single-molecule observations of topotecan-mediated TopIB activity at a unique DNA sequence.
Koster DA; Czerwinski F; Halby L; Crut A; Vekhoff P; Palle K; Arimondo PB; Dekker NH
Nucleic Acids Res; 2008 Apr; 36(7):2301-10. PubMed ID: 18292117
[TBL] [Abstract][Full Text] [Related]
15. Single mutation in the linker domain confers protein flexibility and camptothecin resistance to human topoisomerase I.
Fiorani P; Bruselles A; Falconi M; Chillemi G; Desideri A; Benedetti P
J Biol Chem; 2003 Oct; 278(44):43268-75. PubMed ID: 12904303
[TBL] [Abstract][Full Text] [Related]
16. Three different mutations in the DNA topoisomerase 1B in Leishmania infantum contribute to resistance to antitumor drug topotecan.
Rosa-Teijeiro C; Wagner V; Corbeil A; d'Annessa I; Leprohon P; do Monte-Neto RL; Fernandez-Prada C
Parasit Vectors; 2021 Aug; 14(1):438. PubMed ID: 34454601
[TBL] [Abstract][Full Text] [Related]
17. WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.
Christmann M; Tomicic MT; Gestrich C; Roos WP; Bohr VA; Kaina B
DNA Repair (Amst); 2008 Dec; 7(12):1999-2009. PubMed ID: 18805512
[TBL] [Abstract][Full Text] [Related]
18. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives.
Tanizawa A; Kohn KW; Kohlhagen G; Leteurtre F; Pommier Y
Biochemistry; 1995 May; 34(21):7200-6. PubMed ID: 7766631
[TBL] [Abstract][Full Text] [Related]
19. Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure.
Danks MK; Pawlik CA; Whipple DO; Wolverton JS
Clin Cancer Res; 1997 Oct; 3(10):1731-8. PubMed ID: 9815557
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
Sorensen M; Sehested M; Jensen PB
Br J Cancer; 1995 Aug; 72(2):399-404. PubMed ID: 7640225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
